Introduction
Introduction Statistics Contact Development Disclaimer Help
DTIC AD1033394: Parathyroid Hormone-Related Peptide (PTHrP) as a Ne...
by Defense Technical Information Center
Thumbnail
Download
Web page
The purpose of this study is to investigate the role of
parathyroid hormone-related protein (PTHrP) in cancer
stem cell-driven triple-negative breast cancer. Our goal
is to confirm PTHrP as a targetable molecular driver in
order to develop better therapies against this
notoriously hard-to-treat family of cancers. We have now
constructed animal models with mammary epithelium
fluorescent labelled cells to allow tracing of cancer
stem cells from the primary mammary tumor to the
metastatic site. We will use these models to compare
cancer stem cell behavior in PTHrP-ablated and non-
ablated animals. Using CRISPr technology, we are
developing pre-clinical PTHrP-ablated human triple-
negative breast cancer cell lines to test the cancer-
blocking efficacy of our anti-PTHrP monoclonal antibodies
and identify cell markers associated with cancer
progression events. We are using a large tissue bank from
triple-negative breast cancer patient tumors to
investigate the relationship between triple-negative
breast cancer tumoral PTHrP expression levels and cancer
recurrence. The goal is also to develop a method to
identify patients who would benefit from a novel anti-
PTHrP therapy. We have already determined that PTHrP is
overexpressed in the tumor tissue of the majority of
triple-negative breast cancer cases.
Date Published: 2020-03-19 04:47:54
Identifier: DTIC_AD1033394
Item Size: 11032838
Language: english
Media Type: texts
# Topics
DTIC Archive; Kremer,Richard; Researc...
# Collections
dticarchive
additional_collections
# Uploaded by
@chris85
# Similar Items
View similar items
PHAROS
You are viewing proxied material from tilde.pink. The copyright of proxied material belongs to its original authors. Any comments or complaints in relation to proxied material should be directed to the original authors of the content concerned. Please see the disclaimer for more details.